Technical Analysis for ORIC - Oric Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Inside Day | Range Contraction | 1.37% | |
Wide Bands | Range Expansion | 1.37% | |
Oversold Stochastic | Weakness | 1.37% | |
Wide Bands | Range Expansion | -0.34% | |
Oversold Stochastic | Weakness | -0.34% | |
Stochastic Reached Oversold | Weakness | 3.50% | |
Inside Day | Range Contraction | 3.50% | |
Wide Bands | Range Expansion | 3.50% | |
Oversold Stochastic | Weakness | 3.50% | |
MACD Bearish Centerline Cross | Bearish | 4.24% |
Alert | Time |
---|---|
Down 2 % | about 1 hour ago |
Down 1% | about 1 hour ago |
Rose Above Previous Day's High | about 4 hours ago |
Up 2% | about 4 hours ago |
Up 1% | about 4 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/04/2024
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Oncology Treatment Of Cancer Chemotherapy Occupational Safety And Health Antineoplastic Drugs Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Oncology Treatment Of Cancer Chemotherapy Occupational Safety And Health Antineoplastic Drugs Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 16.63 |
52 Week Low | 6.33 |
Average Volume | 485,742 |
200-Day Moving Average | 10.10 |
50-Day Moving Average | 9.62 |
20-Day Moving Average | 9.31 |
10-Day Moving Average | 9.46 |
Average True Range | 0.71 |
RSI (14) | 41.52 |
ADX | 16.61 |
+DI | 24.13 |
-DI | 24.98 |
Chandelier Exit (Long, 3 ATRs) | 8.97 |
Chandelier Exit (Short, 3 ATRs) | 10.24 |
Upper Bollinger Bands | 10.74 |
Lower Bollinger Band | 7.89 |
Percent B (%b) | 0.3 |
BandWidth | 30.64 |
MACD Line | -0.15 |
MACD Signal Line | -0.03 |
MACD Histogram | -0.1133 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 9.30 | ||||
Resistance 3 (R3) | 9.27 | 9.06 | 9.20 | ||
Resistance 2 (R2) | 9.06 | 8.92 | 9.07 | 9.17 | |
Resistance 1 (R1) | 8.90 | 8.83 | 8.80 | 8.93 | 9.14 |
Pivot Point | 8.69 | 8.69 | 8.64 | 8.70 | 8.69 |
Support 1 (S1) | 8.53 | 8.55 | 8.43 | 8.56 | 8.34 |
Support 2 (S2) | 8.32 | 8.46 | 8.33 | 8.31 | |
Support 3 (S3) | 8.16 | 8.32 | 8.28 | ||
Support 4 (S4) | 8.19 |